Does rilonacept improve resolution and reduce recurrence of pericarditis in patients with recurrent pericarditis?
Rilonacept provides rapid resolution and significantly lowers the risk of recurrence in patients with recurrent pericarditis compared to placebo.
Among patients with recurrent pericarditis, rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo. (Funded by Kiniksa Pharmaceuticals; RHAPSODY ClinicalTrials.gov number, NCT03737110.).
Klein et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: